This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Germany's IQWiG Confirms That ThromboGenics' JETREA® Demonstrates Major Added Value For The Treatment Of Vitreomacular Traction And Macular Hole

LEUVEN, Belgium, August 2, 2013 /PRNewswire/ --

ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that the German Institute for Quality and Efficiency in Health Care (IQWiG) has confirmed that JETREA ® (ocriplasmin) demonstrates major / significant added value in VMT patients with mild / moderately severe symptoms compared with existing comparative treatment, when treating vitreomacular traction (VMT) including when associated with a macular hole of less than or equal to 400 microns.

JETREA ® is the first pharmacological treatment indicated for use in patients diagnosed with VMT and macular hole of diameter less than or equal to 400 microns. It was approved for this indication in the European Union in March 2013. Partner Alcon launched the drug in Germany at the beginning of May.

There are no other pharmacological treatments in development for VMT. Currently patients either have to watch and wait before they are considered eligible for surgery. Surgery is typically performed only at a later stage of a patient's disease, once symptoms progress and their sight deteriorates significantly.  

IQWiG is an independent federal organization that evaluates a drug's quality and efficiency, which makes a recommendation to the Federal Joint Committee (G-BA). G-BA is expected to issue final guidance on JETREA ® in mid-October 2013.

IQWiG recognizes that the data submitted by ThromboGenics in the course of the value assessment provides an indication ( Hinweis) for a major added value for VMT patients with mild symptoms and a significant added value for patients with moderately severe symptoms. Since the introduction of the Early Benefit Assessment in Germany in January 2011, this is the very first time that IQWiG confirms an indication for a major added value ( Hinweis auf einen erheblichen Zusatznutzen) for an innovative new drug substance.

Dr Patrik De Haes, CEO of ThromboGenics, said: " IQWiG ' s assessment confirming the significant additional benefits of JETREA ® for VMT validates the importance of our novel drug in treating patients with this major sight-threatening disease.  For the first time, patients can be treated at an earlier stage of their disease, rather than having to watch and wait until their symptoms worsen. We, and our partner Alcon, look forward to working with G-BA to ensure that the positive benefits shown by JETREA ® are reflected in its final guidance. "   

Earlier this year, JETREA ® was classified as a breakthrough innovation, the highest rating in the so-called 'Fricke and Klaus' assessment 1. This assessment evaluates how innovative the mechanism of action of a new medicine is compared to existing therapies available in Germany.

JETREA ® contains the active substance ocriplasmin. It is administered through a single intravitreal injection to treat adults with vitreomacular traction (VMT).

VMT is a progressive, sight-threatening condition. It is caused by the vitreous humour having an abnormally strong attachment to the macula, the central part of the retina (the light sensitive membrane at the back of the eye). The macula provides central vision that is needed for everyday tasks such as driving, reading and recognizing faces.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.48 -0.84%
FB $100.24 -0.75%
GOOG $675.54 -1.30%
TSLA $153.78 7.00%
YHOO $26.59 -1.90%


Chart of I:DJI
DOW 15,583.55 -331.19 -2.08%
S&P 500 1,816.63 -35.23 -1.90%
NASDAQ 4,225.7820 -57.81 -1.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs